Karl Wurstbauer1, Florian Merz, Felix Sedlmayer. 1. University Clinic of Radiation Oncology, Salzburger Landeskliniken und Paracelsus Medizinische Privatuniversität, Salzburg, Austria. k.wurstbauer@salk.at
Abstract
BACKGROUND AND PURPOSE: Esophagitis is an important side effect in thoracic radiotherapy, no preventive drug therapy has been established yet. The aim of the present study was to prospectively evaluate the effectiveness of prophylactic antimycotic treatment with amphotericin B lozengers. PATIENTS AND METHODS: 40 consecutive patients with high-dose thoracic radiotherapy for lung cancer were investigated in a nonrandomized study. 20 patients receiving a median maximal esophageal dose of 67 Gy (range 61-80 Gy) were treated with amphotericin B lozengers four times daily from day 8 to the end of radiotherapy. Another 20 patients with a lower median maximal esophageal dose of 60 Gy (range 51-67.5 Gy) constituted the control group. Length of the irradiated esophagus and dose-length indices were evaluated. Side effects were prospectively scored according to the RTOG/EORTC criteria. There was a trend toward higher esophageal volumes in the prophylaxis group; furthermore, patients in this group were older, had a worse median Karnofsky Index and had more often received induction chemotherapy. RESULTS: In the prophylaxis group, 15 patients remained free from esophagitis and five patients developed esophagitis grade 1. In the control group, four patients remained free from symptoms, 14 patients showed esophagitis grade 1 and two patients grade 2. The difference between the two groups was statistically significant (p < 0.05). The start of symptoms was delayed in the prophylaxis group in comparison to the control group: day 21 (median, range 14-44) and day 18 (median, range 10-32) respectively. Amphotericin B lozengers were tolerated without side effects by all patients. CONCLUSION: Prophylactic administration of amphotericin B lozengers seems to effectively prevent radiation-induced esophagitis.
BACKGROUND AND PURPOSE:Esophagitis is an important side effect in thoracic radiotherapy, no preventive drug therapy has been established yet. The aim of the present study was to prospectively evaluate the effectiveness of prophylactic antimycotic treatment with amphotericin B lozengers. PATIENTS AND METHODS: 40 consecutive patients with high-dose thoracic radiotherapy for lung cancer were investigated in a nonrandomized study. 20 patients receiving a median maximal esophageal dose of 67 Gy (range 61-80 Gy) were treated with amphotericin B lozengers four times daily from day 8 to the end of radiotherapy. Another 20 patients with a lower median maximal esophageal dose of 60 Gy (range 51-67.5 Gy) constituted the control group. Length of the irradiated esophagus and dose-length indices were evaluated. Side effects were prospectively scored according to the RTOG/EORTC criteria. There was a trend toward higher esophageal volumes in the prophylaxis group; furthermore, patients in this group were older, had a worse median Karnofsky Index and had more often received induction chemotherapy. RESULTS: In the prophylaxis group, 15 patients remained free from esophagitis and five patients developed esophagitis grade 1. In the control group, four patients remained free from symptoms, 14 patients showed esophagitis grade 1 and two patients grade 2. The difference between the two groups was statistically significant (p < 0.05). The start of symptoms was delayed in the prophylaxis group in comparison to the control group: day 21 (median, range 14-44) and day 18 (median, range 10-32) respectively. Amphotericin B lozengers were tolerated without side effects by all patients. CONCLUSION: Prophylactic administration of amphotericin B lozengers seems to effectively prevent radiation-induced esophagitis.
Authors: R Meredith; M Salter; R Kim; S Spencer; B Weppelmann; B Rodu; J Smith; J Lee Journal: Int J Radiat Oncol Biol Phys Date: 1997-01-15 Impact factor: 7.038
Authors: Bernd Gagel; Marc Piroth; Michael Pinkawa; Patrick Reinartz; Michael Zimny; Karin Fischedik; Sven Stanzel; Christian Breuer; Eric Skobel; Branka Asadpour; Axel Schmachtenberg; Ulrich Buell; Michael J Eble Journal: Strahlenther Onkol Date: 2006-05 Impact factor: 3.621
Authors: N Nicolopoulos; A Mantidis; E Stathopoulos; S Papaodysseas; J Kouvaris; H Varveris; C Papavasiliou Journal: Radiother Oncol Date: 1985-01 Impact factor: 6.280
Authors: D De Ruysscher; J Van Meerbeeck; K Vandecasteele; C Oberije; M Pijls; A M C Dingemans; B Reymen; A van Baardwijk; R Wanders; G Lammering; P Lambin; W De Neve Journal: Strahlenther Onkol Date: 2012-04-29 Impact factor: 3.621
Authors: Karl Wurstbauer; Hannes Weise; Heinz Deutschmann; Peter Kopp; Florian Merz; Michael Studnicka; Olaf Nairz; Felix Sedlmayer Journal: Strahlenther Onkol Date: 2010-09-30 Impact factor: 3.621
Authors: Brane Grambozov; Frank Wolf; Julia Kaiser; Romana Wass; Gerd Fastner; Christoph Gaisberger; Lukas Rettenbacher; Michael Studnicka; Christian Pirich; Felix Sedlmayer; Franz Zehentmayr Journal: Thorac Cancer Date: 2019-12-19 Impact factor: 3.500
Authors: Karl Wurstbauer; Heinz Deutschmann; Karin Dagn; Peter Kopp; Franz Zehentmayr; Bernd Lamprecht; Peter Porsch; Birgit Wegleitner; Michael Studnicka; Felix Sedlmayer Journal: Radiat Oncol Date: 2013-03-05 Impact factor: 3.481